Top Markets
#1 Siren Siren +39.86%
#2 RedStone RedStone +23.17%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.68%
#4 Perle Perle +15.69%
#5 Ocean Protocol Ocean Protocol +15.26%
#6 KUB Coin KUB Coin +14.31%
#7 Verus Coin Verus Coin +13.51%
#8 Cysic Cysic +10.93%
#9 Nosana Nosana +10.32%
#10 Quack AI Quack AI +10.31%
Coin of the day
Siren Siren
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE
Rang in Aktien #32097
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Aktienkurs
$0.21483059
Zuletzt synchronisiert: 2024-05-07
Marktkapitalisierung
$11.13M
Veränderung (1 Tag)
0.34%
Veränderung (1 Jahr)
0.00%
Land
CA
Handel Antibe Therapeutics Inc. (ATE)

Kategorie

Healthcare
P/S-Verhältnis für Antibe Therapeutics Inc. (ATE)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Antibe Therapeutics Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Antibe Therapeutics Inc. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
4.13 -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
5.03 -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
2.78 -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
3.67 -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
8.10 -
US